Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
silarivivir potassium
- Development stage
- Unknown
- Lead developer
- Changzhou Yinsheng Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Silarivivir potassium (YS-101) is an orally bioavailable small molecule inhibitor of the Hepatitis C Virus (HCV) NS5A protein. Developed by Changzhou Yinsheng Pharmaceutical, it is designed to disrupt the assembly and replication of the HCV genome. In clinical development, silarivivir potassium is primarily evaluated in combination with other direct-acting antivirals (DAAs), such as the NS3/4A protease inhibitor fobitavir (YS-103), for the treatment of chronic hepatitis C virus infection, particularly genotype 1b. The potassium salt formulation is used to improve the pharmacokinetic profile of the parent compound. Clinical trials in China have focused on its efficacy and safety in treatment-naïve, non-cirrhotic patients.
- Other names
- silarivivir
02
Targets
NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on silarivivir potassium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on silarivivir potassium.